Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XPC-B
- Development stage
- Preclinical
- Lead developer
- Xenon Pharmaceuticals
- Modality
- Small Molecules
01
Overview
XPC-B is a preclinical voltage-gated potassium channel (Kv7) potentiator developed by Xenon Pharmaceuticals as a non-opioid analgesic for the treatment of pain. Comparable to Xenon's clinical-stage candidate XEN1120, XPC-B acts as a positive allosteric modulator of Kv7 (specifically Kv7.2/Kv7.3) channels to reduce neuronal hyperexcitability. In preclinical studies, XPC-B demonstrated dose-dependent efficacy in reducing capsaicin-evoked heat pain in cynomolgus monkeys (a non-human primate model of capsaicin allodynia) at lower plasma exposures than those required in the mouse formalin model, suggesting high potency and potential for translation to human therapeutic doses.
02
Targets
KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)
Beyond the preview
Go deeper on XPC-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XPC-B.